Avicanna Inc. Announces Resignation Of John McVicar And Appoints Ozgur Kilic To Its Board Of Directors

Avicanna Inc. Avicanna Inc., a biopharmaceutical company specializing in the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, announced that John McVicar John McVicar has resigned from his position effective April 1, 2026. At the same time, the Company shared that Mr. Ozgur Kilic Ozgur Kilic has been appointed to its Board of Directors.

Mr. Kilic brings more than two decades of global leadership experience across the pharmaceutical and life sciences sectors. His background includes serving as Chief Executive Officer, as well as holding strategic Chief Financial Officer and Chief Operating Officer roles at several global public companies and private-equity-backed pharmaceutical organizations in the United States, the United Kingdom, Italy, and Switzerland. 

He holds dual bachelor’s degrees in Business Administration and History from Koc University, an MBA in Finance and Investment from the Stuttgart Institute of Management and Technology, and professional designations as an Associate Chartered Management Accountant (ACMA) and Chartered Global Management Accountant (CGMA) through the Chartered Institute of Management Accountants.

Upon his appointment, Mr. Kilic expressed enthusiasm about joining Avicanna’s Board at what he described as a pivotal stage in the Company’s growth. He noted that Avicanna has reached an important inflection point, supported by both its expanding commercial product lineup and its pharmaceutical pipeline targeting significant unmet medical needs. 

He also highlighted the Company’s momentum in advancing its U.S. expansion strategy and strengthening its presence in international markets. Mr. Kilic shared that he looks forward to contributing to Avicanna’s mission of developing innovative cannabinoid-based therapies aimed at improving patient outcomes worldwide.